4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Opus Genetics, Inc. (IRD) operates in the Biotechnology industry and is headquartered in Durham, United States with about 27 employees. Its market capitalization is roughly $331 million. In the fiscal year ended 2025-12-31, IRD reported $14M in revenue and ($50M) in net income.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Interactive charts & full statements → Open the IRD valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $14M | $11M | $19M | $40M | — |
| Operating Income (EBIT) | ($39M) | ($34M) | ($11M) | $18M | — |
| Net Income | ($50M) | ($58M) | ($10M) | $18M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $2M | $4M | $3M | $3M | $4M | — |
| Operating Income (EBIT) | ($14M) | ($12M) | ($8M) | ($9M) | ($10M) | — |
| Net Income | ($66M) | ($16M) | ($18M) | ($7M) | ($8M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $50M | $37M | $54M | $49M | — |
| Total Liabilities | $35M | $30M | $4M | $3M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IRD viewer.
About TickerBase · Data methodology & sources